Deep Genomics news
Deep Genomics, the leading artificial intelligence (AI) therapeutics company, announced today that its Founder and Chief Executive Officer, Brendan Frey, Ph.D., F.R.S.C., will participate in a panel discussion during the Citi PCA – Private Company Digital Health Conference *VIRTUAL* on May 20, 2021.
Details:
- Session: Artificial Intelligence in Drug Discovery
- Date and time: Thursday, May 20, 2021 from 1:3
January 6, 2022. Deep Genomics, the leading AI RNA therapeutics company, today announced that its Founder and CEO, Brendan Frey, PhD, FRSC, will present at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022, at 10:00 a.m. EST.
The presentation will be available as a live webcast through the J.P. Morgan Healthcare Conference portal.
About Deep Genomics
Deep Genomics combines artificial intelligence
Deep Genomics, the leading AI therapeutics company, welcomes Tal Zaks, M.D., Ph.D., to its Strategic Advisory Board, effective today. Deep Genomics uses AI and machine learning to program and prioritize transformational nucleotide-based therapeutics for genetic diseases.
As Chief Medical Officer at Moderna, Zaks successfully led a team that pioneered the field of mRNA therapeutics and drove extraordinary growth, with more than two dozen preclinical and clinical programs advanced durin
Mila, the Quebec Artificial Intelligence Institute, today announced the start of a partnership with Deep Genomics, a leading company in therapeutic artificial intelligence treatments. This collaboration will allow the company to join Mila`s community and to take advantage of the recruitment activities offered by the research institute. Deep Genomics uses AI and machine learning to program and prioritize transformational therapeutics for genetic diseases where unmet medical needs persist. The
- Company expands AI discovery platform for ‘Programmable’ RNA therapeutics and supports advancement of its portfolio into the clinic
- Oversubscribed round led by SoftBank Vision Fund 2, with CPP Investments, Fidelity Management & Research Company LLC, Alexandria Venture Investments, Amplitude Ventures, Khosla Ventures, Magnetic Ventures, and True Ventures
Deep Genomics, the leading artificial intelligence (AI) therapeutics
Deep Genomics, the leading artificial intelligence (AI) therapeutics company, announced today the appointment of Jeffrey Brown, Ph.D., Vice President, Preclinical Research. Jeffrey will be responsible for advancing programs into IND-enabling studies, overseeing the discipline of experimental biology, and working with the leadership team on scientific and business strategies. Fueled by their AI drug discovery and development platform, called the AI Workbench, the company currently has ten prog
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) and Deep Genomics today announced that the companies have entered into a preclinical collaboration that will use Deep Genomics’ artificial intelligence drug discovery platform (The AI Workbench) to identify oligonucleotide drug candidates in four rare disease indications with high unmet need. Deep Genomics will receive an undisclosed upfront payment and is eligible to receive development milestones as a part of the collaborat
- Company also announces appointment of Tom Hughes, Boston-based biotech builder and CEO of Navitor Pharmaceuticals, to board of directors.
- Company now advancing multiple programs in neurodevelopmental, neurodegenerative and metabolic disorders.
Deep Genomics, the leading artificial intelligence (AI) therapeutics company, announced today the appointment of Amanda Kay, Ph.D., to the newly created role of Chief Business Of
Deep Genomics, the leading artificial intelligence (AI) therapeutics company, announced today that Ferdinand Massari, M.D., has been appointed Chief Medical Officer. Dr. Massari is based in Boston and will oversee clinical development and contribute to expanding the company’s AI platform and therapeutic portfolio.
“In a short period of time, our artificial intelligence platform has unlocked dozens of novel therapeutic opportunities for addressing patients with rare genetic
- Led by Future Ventures, includes top healthcare and technology funds Amplitude Ventures, Khosla Ventures, Magnetic Ventures and True Ventures
- Proceeds will support creating new technology for artificial intelligence-accelerated therapeutic development and advancing Wilson disease program into the clinic
Deep Genomics, the leading artificial intelligence (AI) therapeutics company, announced today the closing of its Series B round with $40 mill